Compagnie Lombard Odier SCmA’s Cartesian Therapeutics RNAC Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-317	Closed	-$27K	–	565
2020 Q2	$27K	Hold	317	–	–	﹤0.01%	435
2020 Q1	$23K	Hold	317	–	–	﹤0.01%	398
2019 Q4	$23K	Hold	317	–	–	﹤0.01%	410
2019 Q3	$17K	Hold	317	–	–	﹤0.01%	430
2019 Q2	$17K	Hold	317	–	–	﹤0.01%	431
2019 Q1	$23K	Hold	317	–	–	﹤0.01%	456
2018 Q4	$25K	Hold	317	–	–	﹤0.01%	436
2018 Q3	$148K	Hold	317	–	–	0.01%	321
2018 Q2	$126K	Hold	317	–	–	﹤0.01%	334
2018 Q1	$97K	Sell	317 -316	-50%	-$90K	﹤0.01%	376
2017 Q4	$186K	Buy	633 +233	+58%	+$102K	﹤0.01%	401
2017 Q3	$219K	Buy	+400	New	+$213K	0.01%	354

Other funds holding RNAC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Compagnie Lombard Odier SCmA's RNAC Position: Q3 2020 in Review

Compagnie Lombard Odier SCmA sold out of Cartesian Therapeutics (RNAC) in Q3 2020, closing a stake of 317 shares — an estimated $27K sold.

Compagnie Lombard Odier SCmA first reported a position in RNAC in Q3 2017 and held it in 12 quarters. The position peaked at $219K in Q3 2017. 79 funds tracked by Wall St. Rank hold RNAC as of Q3 2020.

Compagnie Lombard Odier SCmA reported no remaining Cartesian Therapeutics position as of Q3 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 317 Cartesian Therapeutics shares in Q3 2020, an estimated $27K.
Compagnie Lombard Odier SCmA first reported a position in Cartesian Therapeutics in Q3 2017 and held it in 12 quarters.
Compagnie Lombard Odier SCmA's Cartesian Therapeutics position peaked at $219K in Q3 2017.
79 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2020, filed 12 Nov 2020.